Skip to main content
. 2017 Jan 27;7:41525. doi: 10.1038/srep41525

Figure 1. Oridonin depletes BCR-ABL and exhibits anti-proliferative and pro-apoptotic activities in Ph+ leukemia.

Figure 1

(a) Protein array detecting the activity of tyrosine kinases. K562 cells were treated with DMSO (Ctrl) or oridonin (Ori, 20 μM) for 2 h and lysed for hybridization with the protein array. The quantification of BCR-ABL/C-ABL activity is shown in the right panel. (b) Immunoblots showing the activities of BCR-ABL and its downstream pathway in Ph+ leukemia cell lines after a 24-hour treatment with oridonin (20 μM for K562, 10 μM for KU812 and SUP-B15). RABII was used as a loading control. (c) Oridonin downregulates BCR-ABL protein levels in Ph+ cell lines in a time- and concentration-dependent manner as shown by immunoblotting. (d) Tumors from K562 xenograft mice treated with DMSO or oridonin (15 mg/kg) were subjected to immunoblotting. (e) Ph+ cells were treated with oridonin as indicated for 24 hours and cell growth and apoptosis were assessed by MTT assays and Annexin V/PI staining, respectively. **P < 0.01.